Kriya Therapeutics Inc. has presented preclinical data on their novel candidate, KT-A261, an adeno-associated viral vector serotype 2 (AAV2) encoded to express adalimumab, administered as a single intravitreal injection to improve ocular concentrations of adalimumab, for the potential treatment of noninfectious uveitis (NIU).
Glaucoma is an eye disease that damages the optic nerve, with the main cause being ocular hypertension due to high resistance to the outflow of aqueous humor.
New and updated preclinical data presented at the European Society of Gene and Cell Therapy 29th Congress in Edinburgh, Scotland, by: Cellectis, Chameleon, Gentibio, M6P, Vor Biopharma, Voyager Therapeutics.
Researchers from Enanta Pharmaceuticals Inc. presented preclinical data for the small molecule non-nucleoside respiratory syncytial virus (RSV) L-protein inhibitor, EDP-323, being developed for the treatment of RSV infection.
Researchers from Lantern Pharma Inc. presented preclinical data for the small-molecule DNA-damaging agent LP-284, being developed for the treatment of hematological cancers.
While simultaneous targeting of PD-1 and TGF-β has been previously suggested to be a favorable strategy to reverse immune checkpoint inhibitor (ICI) resistance of tumors, the hydrophobicity of TGF-β inhibitors and latent drug-related adverse events of this treatment hindered its utility.
Researchers from the University of Coimbra presented data from a study that aimed to assess the role of the ghrelin/neuropeptide Y (NPY) system in adipose tissue in subjects with obesity and metabolic syndrome.
Cell death induced by hypoxia is quite a common problem during pancreatic islet transplantation and is caused by insufficient revascularization of the grafts. It has been reported that the loss of NLR family pyrin domain containing 3 (NLRP3) in pancreatic islet cells protects them from hypoxia-induced cell death, so it was hypothesized that blockade of NLRP3 would improve pancreatic islet transplantation.
RSS
